EXEL
BULLISH
$44.2
Live
Exelixis, Inc. · NASDAQ
Target $46.83
(+6.0%)
$33.17
52W Range
$49.62
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 09, 2026
Market cap
$11.85B
P/E
15.84
ROE
35.5%
Profit margin
33.7%
Debt/Equity
0.09
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
70%
EXEL shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics.
Key Strengths
Strong profitability (33.7% margin)
Low debt with D/E ratio of 0.09
Strong ROE of 35.5%
Key Risks
Premium vs Graham Number ($22.74)
AI Fair Value Estimate
Based on comprehensive analysis
$82.31
+86.2% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
47
Moderate
50
60
70
55
0
AI Verdict
EXEL shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics.
Key drivers: Strong profitability (33.7% margin), Low debt with D/E ratio of 0.09, Premium vs Graham Number ($22.74)
Confidence
70%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Trades above Graham Number.
Future
60/100
Rule-based growth outlook.
Positives
- Growth-implied value exceeds price.
Watchpoints
No urgent risks highlighted.
Past
70/100
Historical performance + price trend: Shares moved +91.2% over 5Y and +29.5% over 1Y.
Positives
- ROE sits at 35.5%.
- Healthy profit margin of 33.7%.
Watchpoints
No urgent risks highlighted.
Health
55/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Low D/E ratio (0.09).
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$44.2
Analyst Target
$46.83
Upside/Downside
+6.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for EXEL and closest competitors.
Updated 2026-04-08
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
EXEL
Exelixis, Inc.
Primary
|
+91.2% | +119.8% | +29.5% | +14.4% | +4.3% | +0.4% |
|
ALGN
Align Technology, Inc.
Peer
|
-70.6% | -48.8% | +2.3% | +24.8% | -16.9% | -5.6% |
|
ENSG
The Ensign Group, Inc.
Peer
|
+121.6% | +109.3% | +65.7% | +16.2% | -2.4% | +2.3% |
|
BMRN
BioMarin Pharmaceutical Inc.
Peer
|
-27.4% | -41.9% | -20.1% | +4.3% | -5.4% | +4.4% |
|
NBIX
Neurocrine Biosciences, Inc.
Peer
|
+34.2% | +30.1% | +19.1% | -6.2% | -0.5% | +3.0% |
EXE
Exelixis, Inc.
Primary
5Y
+91.2%
3Y
+119.8%
1Y
+29.5%
6M
+14.4%
1M
+4.3%
1W
+0.4%
ALG
Align Technology, Inc.
Peer
5Y
-70.6%
3Y
-48.8%
1Y
+2.3%
6M
+24.8%
1M
-16.9%
1W
-5.6%
ENS
The Ensign Group, Inc.
Peer
5Y
+121.6%
3Y
+109.3%
1Y
+65.7%
6M
+16.2%
1M
-2.4%
1W
+2.3%
BMR
BioMarin Pharmaceutical Inc.
Peer
5Y
-27.4%
3Y
-41.9%
1Y
-20.1%
6M
+4.3%
1M
-5.4%
1W
+4.4%
NBI
Neurocrine Biosciences, Inc.
Peer
5Y
+34.2%
3Y
+30.1%
1Y
+19.1%
6M
-6.2%
1M
-0.5%
1W
+3.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
15.84
Forward P/E
11.25
PEG Ratio
N/A
P/B Ratio
5.37
P/S Ratio
5.11
EV/Revenue
4.58
EV/EBITDA
11.52
Market Cap
$11.85B
Profitability
Profit margins and return metrics
Profit Margin
33.73%
Operating Margin
39.41%
Gross Margin
96.39%
ROE
35.53%
ROA
19.27%
Growth
Revenue and earnings growth rates
Revenue Growth
+5.6%
Earnings Growth
+84.2%
Q/Q Revenue Growth
+5.63%
Q/Q Earnings Growth
+74.8%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.09
Low debt
Current Ratio
3.56
Strong
Quick Ratio
3.35
Excellent
Cash/Share
$4.08
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.6B
Gross Margin
95.6%
Op. Margin
39.4%
Net Margin
40.8%
Total Assets
$2.8B
Liabilities
$0.7B
Equity
$2.2B
Debt/Equity
0.32x
Operating CF
$0.3B
CapEx
$-0.0B
Free Cash Flow
$0.3B
FCF Yield
98%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-12
$N/A
2026-02-10
$0.88
+17.8% surprise
2025-11-04
$0.78
+16.2% surprise
2025-07-28
$0.65
+16.4% surprise
Healthcare Sector Comparison
Comparing EXEL against 189 companies in the Healthcare sector
(17 bullish, 63 neutral, 109 bearish)
P/E Ratio
15.84
This Stock
vs
45.52
Sector Avg
-65.2%
(Discount)
Return on Equity (ROE)
35.53%
This Stock
vs
-44.08%
Sector Avg
-180.6%
(Below Avg)
Profit Margin
33.73%
This Stock
vs
-19.57%
Sector Avg
-272.4%
(Weaker)
Debt to Equity
0.09
This Stock
vs
5.1
Sector Avg
-98.2%
(Less Debt)
Revenue Growth
5.6%
This Stock
vs
108.17%
Sector Avg
-94.8%
(Slower)
Current Ratio
3.56
This Stock
vs
3.39
Sector Avg
+4.9%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
EXEL
Exelixis, Inc.
|
BULLISH | $11.85B | 15.84 | 35.5% | 33.7% | $44.2 | |
|
ALGN
Align Technology, Inc.
|
NEUTRAL | $11.78B | 29.07 | 10.4% | 10.2% | $164.23 | Compare |
|
ENSG
The Ensign Group, Inc.
|
NEUTRAL | $11.96B | 34.36 | 16.9% | 6.8% | $204.79 | Compare |
|
BMRN
BioMarin Pharmaceutical Inc.
|
NEUTRAL | $10.86B | 32.28 | 5.9% | 10.8% | $56.49 | Compare |
|
NBIX
Neurocrine Biosciences, Inc.
|
BULLISH | $13.22B | 28.15 | 16.4% | 16.7% | $131.74 | Compare |
EXEL
Exelixis, Inc.
BULLISH
Mkt Cap
$11.9B
P/E
15.8
ROE
35.5%
Price
$44.2
ALGN
Align Technology, Inc.
NEUTRAL
Mkt Cap
$11.8B
P/E
29.1
ROE
10.4%
Price
$164.23
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-26 | MORRISSEY MICHAEL M | Chief Executive Officer | Stock Award | 160,437 | - |
| 2026-02-26 | HALEY PATRICK JOSEPH | Officer | Stock Award | 40,459 | - |
| 2026-02-26 | AFTAB T DANA | Officer | Stock Award | 52,018 | - |
| 2026-02-26 | HEFTI BRENDA | General Counsel | Stock Award | 23,119 | - |
| 2026-02-26 | SENNER CHRISTOPHER J. | Chief Financial Officer | Stock Award | 52,018 | - |
| 2026-02-24 | MORRISSEY MICHAEL M | Chief Executive Officer | Gift | 100,278 | - |
| 2026-02-24 | AFTAB T DANA | Officer | Sale | 47,918 | $2,132,351 |
| 2026-02-19 | AFTAB T DANA | Officer | Sale | 29,873 | $1,324,868 |
| 2026-02-18 | MORRISSEY MICHAEL M | Chief Executive Officer | Gift | 375,830 | - |
| 2026-02-18 | WYSZOMIERSKI JACK L | Director | Sale | 99,574 | $4,382,252 |
| 2026-02-18 | WYSZOMIERSKI JACK L | Director | Option Exercise | 20,634 | $407,934 |
| 2026-02-18 | HEFTI BRENDA | General Counsel | Sale | 18,669 | $821,623 |
| 2026-02-18 | SMITH JULIE ANNE | Director | Sale | 106,539 | $4,687,346 |
| 2026-02-18 | SMITH JULIE ANNE | Director | Option Exercise | 106,539 | $2,060,954 |
| 2026-02-17 | HALEY PATRICK JOSEPH | Officer | Sale | 67,814 | $2,950,941 |
MORRISSEY MICHAEL M
Chief Executive Officer
2026-02-26
160,437 shares
HALEY PATRICK JOSEPH
Officer
2026-02-26
40,459 shares
AFTAB T DANA
Officer
2026-02-26
52,018 shares
HEFTI BRENDA
General Counsel
2026-02-26
23,119 shares
SENNER CHRISTOPHER J.
Chief Financial Officer
2026-02-26
52,018 shares
MORRISSEY MICHAEL M
Chief Executive Officer
2026-02-24
100,278 shares
AFTAB T DANA
Officer
2026-02-24
47,918 shares
·
$2,132,351
AFTAB T DANA
Officer
2026-02-19
29,873 shares
·
$1,324,868
MORRISSEY MICHAEL M
Chief Executive Officer
2026-02-18
375,830 shares
WYSZOMIERSKI JACK L
Director
2026-02-18
99,574 shares
·
$4,382,252
WYSZOMIERSKI JACK L
Director
2026-02-18
20,634 shares
·
$407,934
HEFTI BRENDA
General Counsel
2026-02-18
18,669 shares
·
$821,623
SMITH JULIE ANNE
Director
2026-02-18
106,539 shares
·
$4,687,346
SMITH JULIE ANNE
Director
2026-02-18
106,539 shares
·
$2,060,954
HALEY PATRICK JOSEPH
Officer
2026-02-17
67,814 shares
·
$2,950,941
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
18 analysts
RBC Capital
2026-03-02
Sector Perform
Sector Perform
HC Wainwright & Co.
2026-02-12
Buy
Buy
RBC Capital
2026-02-11
Sector Perform
Sector Perform
Stifel
2026-02-11
Hold
Hold
Wells Fargo
2026-02-11
Equal-Weight
Equal-Weight
Barclays
2026-02-04
Equal-Weight
Equal-Weight
HC Wainwright & Co.
2026-02-03
Buy
Buy
Morgan Stanley
2026-02-02
Equal-Weight
Equal-Weight
HC Wainwright & Co.
2026-01-27
Buy
Buy
HC Wainwright & Co.
2026-01-08
Buy
Buy
Past News Coverage
Recent headlines mentioning EXEL from our newsroom.
Newest → oldest
No matching news yet.